Cargando…
Aneurysm characteristics and risk of rebleeding after subarachnoid haemorrhage
INTRODUCTION: Knowledge of risk factors for rebleeding after aneurysmal subarachnoid haemorrhage can help tailoring ultra-early aneurysm treatment. Previous studies have identified aneurysm size and various patient-related risk factors for early (≤24 h) rebleeding, but it remains unknown if aneurysm...
Autores principales: | Koopman, Inez, Greving, Jacoba P, van der Schaaf, Irene C, van der Zwan, Albert, Rinkel, Gabriel JE, Vergouwen, Mervyn DI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572641/ https://www.ncbi.nlm.nih.gov/pubmed/31259263 http://dx.doi.org/10.1177/2396987318803502 |
Ejemplares similares
-
CompLement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Haemorrhage (CLASH): study protocol for a randomised controlled phase II clinical trial
por: Koopman, Inez, et al.
Publicado: (2020) -
Devastating delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
por: Koopman, Inez, et al.
Publicado: (2022) -
Rebleeding After Aneurysmal Subarachnoid Hemorrhage in Two Centers Using Different Blood Pressure Management Strategies
por: Calviere, Lionel, et al.
Publicado: (2022) -
Difference in Aneurysm Characteristics between Patients with Familial and Sporadic Aneurysmal Subarachnoid Haemorrhage
por: Mensing, Liselore A., et al.
Publicado: (2016) -
Safety and pharmacodynamic efficacy of eculizumab in aneurysmal subarachnoid hemorrhage (CLASH): A phase 2a randomized clinical trial
por: Koopman, Inez, et al.
Publicado: (2023)